End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.32 CNY | +0.14% | -2.53% | -8.50% |
May. 14 | GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO… | RE |
Apr. 29 | Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.50% | 6.67B | C- | ||
-2.99% | 89.69B | A- | ||
+2.50% | 41.34B | A- | ||
-12.01% | 33.72B | B- | ||
+62.74% | 26.11B | A | ||
-19.79% | 14.63B | C | ||
-8.58% | 12.84B | B- | ||
-12.34% | 11.66B | D+ | ||
-43.92% | 11.52B | B | ||
+4.27% | 8.92B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002252 Stock
- Ratings Shanghai RAAS Blood Products Co., Ltd.